Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 310
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT02220725 | A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban | ||
| NCT04970004 | Study in Adult and Pediatric Patients With HSCT-TMA | ||
| NCT04557735 | Study of Ravulizumab in Pediatric Participants With HSCT-TMA | ||
| NCT07306949 | Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers | ||
| NCT04560816 | A Study of the Cardiac Effects of ALXN1840 in Healthy Adults | ||
| NCT04660890 | A Study of the Cardiac Effects of ALXN2050 in Healthy Adults | ||
| NCT06291376 | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | ||
| NCT04709081 | A Drug Interaction Study of ACH-0145228 | ||
| NCT04631562 | Study of ALXN1820 in Healthy Adult Participants | ||
| NCT03330457 | A Healthy Volunteer PK/PD, Safety and Tolerability Study of Andexanet After Betrixaban Dosing | ||
| NCT01919346 | Eculizumab for Prevention of Delayed Graft Function (DGF) in Kidney Transplantation | ||
| NCT01229254 | Evaluate the Pharmacokinetics and Safety of MK-4448 in Participants With Nonvalvular Atrial Fibrillation or Atrial Flutter | ||
| NCT04504825 | A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | ||
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | ||
| NCT05982938 | Danicopan Early Access Program | ||
| NCT03406507 | A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria | ||
| NCT05565092 | Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Study of ALXN1820 in Adult Participants With Sickle Cell Disease | ||
| NCT01410916 | Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS) | ||
| NCT02372513 | National Lysosomal Acid Lipase Deficiency Study | ||
| NCT01275287 | Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab | ||
| NCT02949128 | Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | ||
| NCT02614898 | Evaluation of Potential Predictors of Disease Progression in Participants With Atypical Hemolytic Uremic Syndrome (aHUS) Including Genetics, Biomarkers, and Treatment | ||
| NCT00844844 | Open Label Controlled Trial of Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS | ||
| NCT05428696 | Safety and Tolerability, PK, and PD Study of Single and Multiple ALXN2080 Doses in Healthy Participants | ||
| NCT01374360 | Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry | ||
| NCT06173596 | A Study to Evaluate Potential Drug Interactions Between ALXN2080 and Itraconazole, Fluconazole & Carbamazepine in Healthy Adults | ||
| NCT00670774 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant | ||
| NCT01106027 | Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Crossmatch Deceased Donor Kidney Transplant | ||
| NCT00037622 | Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection. | ||
| NCT04202341 | Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | ||
| NCT05097989 | Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) | ||
| NCT04743804 | Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger | ||
| NCT00380159 | Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A | ||
| NCT06830798 | Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | ||
| NCT06079281 | Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | ||
| NCT01221181 | Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy | ||
| NCT05644561 | Evaluation of PK, PD, Efficacy, Safety, and Immunogenicity of IV Ravulizumab in Pediatric Participants With Generalized Myasthenia Gravis | ||
| NCT01335165 | Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT02796885 | Characterisation of Adult-Onset Hypophosphatasia | ||
| NCT01567085 | Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor | ||
| NCT05368038 | ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | ||
| NCT05288816 | A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants | ||
| NCT04925804 | Unraveling Genetics of HypoPhosPhatasia (HPP Genetics) | ||
| NCT06724809 | Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD | ||
| NCT02946463 | ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) | ||
| NCT05218096 | Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis | ||
| NCT03748823 | Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | ||
| NCT04526210 | Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants | ||
| NCT05259085 | Study of ALXN2050 in Participants With Hepatic Impairment | ||
| NCT04189315 | Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease |
